Zoledronic acid Teva Pharma (zoledronic acid)
Generic
- Region
- 🇪🇺 EU
- Active substance
- zoledronic acid
- Company
- Teva B.V.
- Status
- Withdrawn
- Therapeutic area
- Osteoporosis; Osteitis Deformans; Osteoporosis, Postmenopausal
- EU approval
- Wed 15 Aug 2012
- Designations
- Generic
- Application
- EMEA/H/C/002437
- ATC
- M05BA08
- Official record
- www.ema.europa.eu
Indication
Treatment of osteoporosis: in post-menopausal women; in men; at increased risk of fracture including those with a recent low-trauma hip fracture. Treatment of osteoporosis associated with long-term systemic glucocorticoid therapy: in post-menopausal women; in men; at increased risk of fracture. Treatment of Paget’s disease of the bone in adults.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Zoledronic acid Mylan Authorised · Mylan Pharmaceuticals Limited
- 🇪🇺 Zoledronic acid Teva Authorised · Teva B.V.
- 🇪🇺 Zoledronic acid Actavis Withdrawn · Actavis Group PTC ehf
- 🇪🇺 Zoledronic acid medac Withdrawn · medac Gesellschaft für klinische Spezialpräparate mbH
- 🇪🇺 Zoledronic Acid Hospira Withdrawn · Pfizer Europe MA EEIG
- 🇪🇺 Aclasta Authorised · Sandoz Pharmaceuticals d.d.
- 🇪🇺 Zoledronic Acid Accord Authorised · Accord Healthcare S.L.U.
- 🇪🇺 Zometa Authorised · Phoenix Labs Unlimited Company
- 🇪🇺 Zoledronic acid Teva Generics Withdrawn · Teva Generics B.V
Follow Zoledronic acid Teva Pharma
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.